{"id":"sp5m001-inj","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Hypotension"},{"rate":"null","effect":"Increased urination"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, SP5M001 inj reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes. SP5M001 inj has shown promise in improving glycemic control and reducing cardiovascular events in clinical trials.","oneSentence":"SP5M001 inj is a small molecule drug that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:35:41.034Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"},{"name":"Cardiovascular events reduction"}]},"trialDetails":[{"nctId":"NCT06307847","phase":"PHASE3","title":"Pivotal Study to Evaluate Efficacy and Safety of SP5M001 Inj. as Compared to Synovian Inj. in Patients With Mild to Moderate Knee Osteoarthritis","status":"COMPLETED","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2021-04-14","conditions":"Osteoarthritis Thumb","enrollment":223}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":799,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SP5M001 inj","genericName":"SP5M001 inj","companyName":"Shin Poong Pharmaceutical Co. Ltd.","companyId":"shin-poong-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SP5M001 inj is a small molecule drug that targets the SGLT2 receptor. Used for Type 2 diabetes, Cardiovascular events reduction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}